The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 21, 2025
Filed:
Apr. 01, 2020
The University of Chicago, Chicago, IL (US);
The United States of America, As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);
President and Fellows of Harvard College, Cambridge, MA (US);
Iit Research Institute, Chicago, IL (US);
Beth Israel Deaconess Medical Center, Inc., Boston, MA (US);
Regents of the University of Minnesota, Minneapolis, MN (US);
The Trustees of Purdue University, Lafayette, IN (US);
Julian Solway, Glencoe, IL (US);
Nickolai Dulin, Chicago, IL (US);
Diane Luci, Germantown, MD (US);
David Maloney, Point of Rocks, MD (US);
Chan Young Park, Belmont, MA (US);
Jeffrey Fredberg, Newton, MA (US);
David McCormick, Chicago, IL (US);
Ramaswamy Krishnan, Boston, MA (US);
The University of Chicago, Chicago, IL (US);
The United States of America, as Represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US);
President and Fellows of Harvard College, Cambridge, MA (US);
IIT Research Institute, Chicago, IL (US);
Beth Israel Deaconess Medical Center Inc., Boston, MA (US);
Abstract
Disclosed herein is a class of molecules termed remodilins that are effective in treating asthma, pulmonary fibrosis, and associated disorders. The molecules ameliorate asthma and pulmonary fibrosis symptoms by various mechanisms, including inhibiting airway smooth muscle contractile protein accumulation, reducing airway constrictor hyperresponsiveness, inhibiting bronchial fibroblast transformation into myofibroblasts, and/or treating or preventing airway or pulmonary fibrosis.